KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 176 filers reported holding KITE PHARMA INC in Q1 2016. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $16,549,000 | +69.4% | 159,631 | +28.3% | 0.12% | +68.1% |
| Q1 2017 | $9,767,000 | -53.3% | 124,436 | -73.3% | 0.07% | -55.3% |
| Q4 2016 | $20,918,000 | +57.5% | 466,492 | +96.2% | 0.16% | +51.9% |
| Q3 2016 | $13,279,000 | +21.5% | 237,718 | +8.7% | 0.11% | +17.8% |
| Q2 2016 | $10,930,000 | -46.9% | 218,601 | -51.2% | 0.09% | -45.1% |
| Q1 2016 | $20,565,000 | +30.0% | 447,941 | +74.5% | 0.16% | +25.2% |
| Q4 2015 | $15,822,000 | -61.5% | 256,764 | -65.2% | 0.13% | -62.1% |
| Q3 2015 | $41,096,000 | -32.3% | 738,066 | -25.9% | 0.35% | -20.6% |
| Q2 2015 | $60,702,000 | +45.6% | 995,604 | +37.7% | 0.44% | +44.9% |
| Q1 2015 | $41,690,000 | +175.7% | 722,774 | +175.6% | 0.30% | +171.2% |
| Q4 2014 | $15,124,000 | +354.4% | 262,249 | +124.6% | 0.11% | +311.1% |
| Q3 2014 | $3,328,000 | +37.1% | 116,775 | +39.1% | 0.03% | +50.0% |
| Q2 2014 | $2,428,000 | – | 83,960 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |